TM
CTNM

Torren Management’s Contineum Therapeutics CTNM Stock Holding History

Torren Management’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.16K Hold
254
– – ﹤0.01% 387
2026
Q1 		$3.32K Sell
254
-1,308
-84% -$17.5K ﹤0.01% 417
2025
Q4 		$17.9K Buy
+1,562
New +$17.8K 0.01% 610

Other funds holding CTNM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return
IFG
Independent Financial Group San Diego, California $5.35B AUM 43.78% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Torren Management's CTNM Position: Q2 2026 in Review

Torren Management held its Contineum Therapeutics (CTNM) position steady in Q2 2026 at 254 shares worth $4.16K. The position accounts for ﹤0.01% of the portfolio, ranked #387.

Torren Management first reported a position in CTNM in Q4 2025 and has held it in 3 quarters since. The position peaked at $17.9K in Q4 2025. 21 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • Torren Management held 254 shares of Contineum Therapeutics worth $4.16K as of Q2 2026.
  • Torren Management left its Contineum Therapeutics share count unchanged in Q2 2026.
  • Contineum Therapeutics made up ﹤0.01% of Torren Management's portfolio in Q2 2026, its #387 holding.
  • Torren Management first reported a position in Contineum Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Torren Management's Contineum Therapeutics position peaked at $17.9K in Q4 2025.
  • 21 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Torren Management's 13F filing for Q2 2026, filed 10 Jul 2026.